New findings: Depression, suicide, and Toxoplasma gondii infection

Journal of the American Association of Nurse Practitioners

Volumn 26, Issue 11, 2014, Pages 629-637

  Hsu, Pao Chu ^a   Groer, Maureen ^a   Beckie, Theresa ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dopamine; IDO; Proinflammatory cytokines; Serotonin; Tryptophan

Indexed keywords

DEPRESSION; HUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; PSYCHOLOGY; SUICIDE; TOXOPLASMA; TOXOPLASMOSIS;

DEPRESSION; HUMANS; SUICIDE; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84910104957     PISSN: 23276886     EISSN: 23276924     Source Type: Journal    
DOI: 10.1002/2327-6924.12129     Document Type: Review

References (67)

1. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorder Text-Revision DSM-IV-TR (4th ed.). Washington, DC: American Psychiatric Association.
2. Arling, T. A., Yolken, R. H., Lapidus, M., Langenberg, P., Dickerson, F. B., Zimmerman, S. A., & Postolache, T. T. (2009). Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. Journal of Nervous and Mental Disease, 197, 905-908.
3. Alesci, S., Martinez, P. E., Kelkar, S., Llias, L., Ronsaville, D. S., Listwak, S. J., & Gold, W. (2005). Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian in its secretion: Clinical implications. Journal of Clinical Endocrinology and Metabolism, 90, 2522-2530.
4. Brown, A. S., Schaefer, C. A., Quesenberry, C. P., Liu, L., Babulas, V. P., & Susser, E. S. (2005). Maternal exposure to Toxoplasmosis and risk of schizophrenia in adult offspring. American Journal of Psychiatry, 162, 767-773.
5. Capuron, L., & Miller, A. H. (2011). Immune system to brain signaling: Neuropsychophamacological implications. Pharmacology & Therapeutics, 130, 226-238.
6. Capuron, L., Schroecksnadel, S., Feart, C., Aubert, A., Higueret, D., Barberger-Gateau, P., & Fuchs, D. (2011). Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: Role in neuropsychiatric symptoms. Biological Psychiatry, 70, 175-182.
7. Carruthers, V. B., & Suzuki, Y. (2007). Effects of Toxoplasma gondii infection on the brain. Schizophrenia Bulletin, 33, 745-751.
8. Centers for Disease Control and Prevention (CDC). (2013a). Suicide and self-inflicted injury. Retrieved from http://www.cdc.gov/nchs/fastas/suicide.htm.
9. Centers for Disease Control and Prevention (CDC). (2013b). Toxoplasmosis. Retrieved from http://www.cdc.gov/parasites/toxoplasmosis/.
10. Centers for Disease Control and Prevention (CDC). (2013c). Parasites-toxoplasmosis. Resources for health professionals. Retrieved from http://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html#tx.
11. Chaplin, D. D. (2010). Overview of the immune response. Journal of Allergy and Clinical Immunology, 125, S3-S25.
12. Dalimi, A., & Abdoli, A. (2012). Latent toxoplasmosis and human. Iranian Journal of Parasitology, 7, 1-17.
13. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9, 46-57.
14. Dubey, J. P., & Jones, J. L. (2008). Toxoplasma gondii infection in humans and animals in the United States. International Journal for Parasitology, 38, 1257-1278.
15. Elbez-Rubenstein, A. (2009). Congenital toxoplasmosis and reinfection during pregnancy: Case report, strain characterization, experimental model of reinfection, and review. Journal of Infectious Diseases, 199, 280-285.
16. Fekadu, A. Shibre, T., & Cleare, A. J. (2010). Toxoplasmosis as a cause for behavior disorders-Overview of evidence and mechanism. Folia Parasitologica, 57, 105-113.
17. Felger, J. C., Li, L., Marvar, P. J., Woolwine, B. J., Harrison, D. G., Raison, C. L., & Miller, A. H. (2013). Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Brain, Behavior, and Immunity, 31, 153-160.
18. Flegr, J. (2013a). Influence of latent Toxoplasma infection on human personality, physiology and morphology: Pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. Journal of Experimental Biology, 216, 127-133.
19. Flegr, J. (2013b). How and why Toxoplasma makes us crazy. Trends in Parasitology, 29, 156-183.
20. Gaskell, E. A., Smith, J. E., Pinney, J. W., Westhead, D. R., & McConkey, G. A. (2009). A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One, 4, e4801
21. Goodwin, D. G., Strobl, J. S., & Lindsay, D. S. (2011). Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. Journal of Parasitology, 97, 148-151.
22. Groer, M., Yolken, R. H., Beckstead, J. W., Fuchs, D., Mohapatra, S. S., Seyfang, A., & Postolache, T. T. (2011). Prenatal depression and anxiety in Toxoplasma gondii positive women. American Journal of Obstetrics Gynecology, 204(5), 433-e1-433-e7.
23. Haroon, E., Raison, C. L., & Miller, A. H. (2012). Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology, 37, 137-162.
24. Henriquez, S. A., Brett, R., Alexander, J., Pratt, J., & Roberts, C. W. (2009). Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation, 16, 122-133.
25. Hinze-Selch, D., Daubener, W., Erdag, S., & Wilms, S. (2010). The diagnosis of a personality disorder increases the likelihood for seropositivity to Toxoplasma gondii in psychiatric patients. Folia Parasitologica, 57, 129-135.
26. Hotop, A. Hlobil, H., & GroB, U. (2012). Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clinical Infectious Diseases, 54, 1545-1552.
27. Hurley, R. A., & Taber, K. H. (2012). Latent Toxoplasmosis gondii: Emerging evidence for influences on neuropsychiatric disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 24, 376-383.
28. Janelidz, S., Mattei, D., Westrin, A., Traskman-Bendz, L., & Brundin, L. (2010). Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain, Behavior, and Immunity, 25, 335-339.
29. Jones-Brando, L., Torrey, E. F., & Yolken, R. (2003). Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophrenia Research, 62, 237-244.
30. Kar, N., & Misra, B. (2004). Toxoplasma seropositivity and depression: A case report. BMC Psychiatry, 4, 1-2.
31. Kelly, K. W., Bluthe, R. M., Dantzer, R., Zhou, J. H., Shen, W. H., Johnson, R. W., & Broussard, S. R. (2003). Cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 17, S112-S118.
32. Kenna, G. A., Roder-Hanna, N., Zywiak, W. H., Clifford, J., Edwards, S., Kenna, J. A., & Swift, R. M. (2012). Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: Review of psychopathology and pharmacotherapy. Pharmacogenomics and Personalized Medicine, 5, 19-35.
33. Kim, K., & Weiss, L. M. (2008). Toxoplasma: The next 100 years. Microbes and Infection, 10(9), 978-984.
34. Kodjikian, L., Hoigne, I., Adam, O., Jacquier, P., Aebi-Ochsner, C., Aebi, C., & Garweg, J. G. (2004). Vertical transmission of toxoplasmosis from a chronically infected immunocompetent woman. Pediatric Infectious Diseases Journal, 23(3), 272-274.
35. Krishnadas, R., & Cavanagh, J. (2012). Depression: An inflammatory illness? Journal of Neurology, Neurosurgery & Psychiatry, 83, 495-502.
36. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16, 606-613.
37. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2003). The Patient Health Questionnaire-2: Validity of a two-item depression screener. Medical Care, 41, 1284-1294.
38. Ling, V. J., Lester, D., Mortensen, P. B., Langenberg, P. W., & Postolache, T. T. (2011). Toxoplasma gondii seropositivity and suicide rates in women. Journal of Nervous and Mental Disease, 199, 440-444.
39. Lopes, F. M. R., Goncalves, D. D., Mitsuka-Bregano, R., Freire, R. L., & Navarro, I. T. (2007). Toxoplasma gondii infection in pregnancy. Brazilian Journal of Infectious Diseases, 11(5), 496-506.
40. Mann, J. J. (2003). Neurobiology of suicidal behavior. Nature Reviews Neuroscience, 4, 819-828.
41. Matzinger, P. (2002). The danger model: A renewed sense of self. Science, 296, 301-305.
42. Montoya, J. G., & Remington, J. S. (2008). Management of Toxoplasma gondii infection during pregnancy. Clinical Infectious Diseases, 47, 554-566.
43. Mortensen, P. B., Norgaard-Pedersen, B., Waltoft, B. L., Sorensen, T. L., Hougaard, D. Torrey, E. F., & Yolken, R. H. (2007). Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biological Psychiatry, 61, 688-693.
44. Muller, N., & Schwarz, M. J. (2007). The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Molecular Psychiatry, 12, 988-1000.
45. Muller, N., Ulmschneider, M., Scheppach, C., Schwarz, M. J., Ackenheil, M., Moller, H. J., & Riedel, M. (2004). Cox-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience, 254, 14-22.
46. Okusaga, O., Langenberg, P., Sleemi, A., Vaswoni, D., Giegling, I., Hartmann, A. M., & Postolache, T. T. (2011). Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophrenia Research, 133, 150-155.
47. Okusaga, O., & Postolache, T. T. (2012). Chapter 19 Toxoplasma gondii, the immune system, and suicidal behavior. In Y. Dwivedi (Ed.), The neurobiological basis of suicide (pp. 1-16). Boca Raton, FL: CRC Press.
48. Pappas, G., Roussos, N., & Falagas, M. E. (2009). Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International Journal for Parasitology, 39, 1385-1394.
49. Pratt, L. A., & Brody, D. J. (2008). Depression in the United States household population, 2005-2006. National Center for Health Statistics Data Brief, 7, 1-8.
50. Raison, C. L., Capuron, L., & Miller, A. H. (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trend in Immunology, 27, 24-31.
51. Raison, C. L., & Miller, A. H. (2011). Is depression an inflammatory disorder? Current Psychiatry Reports, 13, 467-475.
52. Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005). Cytokine and major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29, 201-217.
53. Schmidt, H. D., Shelton, R., & Duman, R. S. (2011). Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology, 36, 2375-2394.
54. Soleimani, L., Lapidus, K., & Iosifescu, D. V. (2011). Diagnosis and treatment of major depressive disorder. Neurologic Clinics, 29, 177-193.
55. Sperner-Unterweger, B., Kohl, C., & Fuchs, D. (2014). Immune changes and neurotransmitters: Possible interactions in depression? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 48, 268-276.
56. Tedla, Y., Shibre, T., Ali, O., Tadele, G., Woldeamamuel, Y., Asrat, D., & Habte, A. (2011). Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case-control study. Ethiopian Medical Journal, 49, 211-220.
57. Torrey, E. F., Bartko, J. J., Lun, Z. R., & Yolken, R. H. (2007). Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 33, 729-736.
58. Tyring, S., Gottieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., & Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo controlled randomized phase III trial. Lancet, 367, 29-35.
59. United States Department of Veterans Affairs (VA/DoD). (2009). VA/DoD depression practice guidelines: Management of major depressive disorder. Retrieved from http://www.healthquality.va.gov/mdd/.
60. Webster, J. P., Lamberton, P. H. L., Donnelly, C. A., & Torrey, E. F. (2006). Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behavior. Proceedings of the Royal Society Biological Sciences, 273, 1023-1030.
61. Webster, J. P., & McConkey, G. A. (2003). Toxoplasma gondii-altered host behavior: Clue as to mechanism of action. Folia Parasitologica, 57, 95-104.
62. World Health Organization (WHO). (2013). Depression. Retrieved from http://www.who.int/mediacentre/factsheets/fs369/en/.
63. Xiao, J., Buka, S. L., Cannon, T. D., Suzuki, Y., Viscidi, R. P. Torrey, E. F., & Yolken, R. H. (2009). Serological pattern consistent with infection with type 1 Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes and Infection, 11, 1011-1018.
64. Yolken, R. H., & Torrey, E. F. (2008). Are some cases of psychosis caused by microbial agents? A review of the evidence. Molecular Psychiatry, 13, 470-479.
65. Zalcman, S. S., & Siegel, A. (2006). The neurobiology of aggression and rage: Role of cytokines. Brain, Behavior, and Immunity, 20, 507-514.
66. Zhang, Y., Traskman-Bendz, L., Janelidze, S., Langenberg, P., Saleh, A., Constantine, N., & Postolache, T. T. (2012). Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. Journal of Clinical Psychiatry, 73, 1069-1076.
67. Zhu, S. (2009). Psychosis may be associated with toxoplasmosis. Medical Hypotheses, 73, 799-801.